Noveris Health Sciences Inc., a biotechnology company, engages in developing and commercializing solutions for treating mental health problems and enhancing vitality. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. Noveris Health Sciences Inc. was formerly known as Mydecine Innovations Group Inc. and changed its name to Noveris Health Sciences Inc. in February 2026. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.
Frequently asked questions
What sector does Mydecine Innovations Group Inc (MYCOF) operate in?
Mydecine Innovations Group Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Mydecine Innovations Group Inc (MYCOF) current stock price?
As of the latest data, Mydecine Innovations Group Inc stock price is $0.73, with a previous close of $0.73.
What is Mydecine Innovations Group Inc (MYCOF) current market capitalization?
Mydecine Innovations Group Inc market cap is approximately 42.74 million.
What is Mydecine Innovations Group Inc (MYCOF) Earnings Per Share (EPS)?
The trailing EPS is $1.89.
What is Mydecine Innovations Group Inc (MYCOF) Price-to-Earnings (P/E) ratio?
Mydecine Innovations Group Inc current P/E ratio is 0.39.
What is Mydecine Innovations Group Inc (MYCOF) EBITDA?
Mydecine Innovations Group Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -492.38 thousand.
Does Mydecine Innovations Group Inc (MYCOF) pay dividends?
No. Mydecine Innovations Group Inc does not pay a dividend.
What is Mydecine Innovations Group Inc (MYCOF) beta (volatility) score?
Mydecine Innovations Group Inc has a beta of -5.515, indicating lower volatility than the overall market.
